Skip to main content

Table 4 Dose and infection-type dependent risk of infection in patients treated with fremanezumab vs. placebo

From: Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment

Fremanezumab dose

Statistics

Infection

Any

Viral

Bacterial

COVID-19

Urinary

Any

p- value

0.900

0.894

0.960

-

0.812

RR

1.01

0.99

1.01

 

1.08

Clinical

p-value

0.457

0.429

0.625

-

0.646

RR

1.08

1.07

1.15

 

1.18

High

p- value

0.855

0.602

0.650

-

0.345

RR

0.99

0.95

1.12

 

1.37

  1. COVID-19 - Coronavirus disease 2019; UTI– urinary tract infection; RR– risk ratio
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us